Long-term safety of tyrosine kinase inhibitors in chronic myeloid leukemia patients

Jee Hyun Kong

Yonsei University College of Medicine, Korea

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML), changing it from a life-threatening disease to one with life expectancies similar to the general population. Although these treatments have dramatically changed the natural course of CML, they may result in cardiovascular and/or metabolic complications. Now, to avoid these long-term complications, the focus of treatment has shifted to TKI discontinuation.

Here, we will review the long-term complication of currently available TKIs, and present incidence of long-term complication of TKIs in Korean CML patients using National Health Information Database.